abstract |
The present invention relates to aglycosyl anti-CD154 antibodies or antibody derivatives characterized by modifications at conserved N-linked sites in the C H2 domain of the Fc portion of the antibody. The invention also relates to treating diseases associated with immune responses and to inhibiting unwanted immune responses with said aglycosylated anti-CD154 antibody or antibody derivatives thereof. |